Targeting Lung Adenocarcinoma

Nanoparticles with nanocarriers act as novel delivery systems have the possibility of cell-targeted drug delivery with minimal systemic side effects and toxicity. As a leading service provider of high-quality targeted delivery systems, Creative Biolabs has years of experience in the field of targeted delivery and we provide advanced module delivery systems for our clients. With combined expertise in protein chemistry, immunology, and molecular biology, our scientific team can help you with every step of the development process, from design to validation.

Lung Adenocarcinoma

Lung cancer is the most chronic disease among all other airways and lung disease and one of the leading causes of death worldwide. Lung cancer cells include small-cell (SCLC) and non-small-cell lung carcinomas (NSCLC). NSCLC can be further subdivided into adenocarcinomas (AD), largecell carcinomas (LC), and squamous cell carcinomas (SQ). Lung cancer is common in both men and women who are exposed to both direct and indirect smoking group. Currently, the 5-year survival rate increased significantly via the incorporation of modern chemotherapy regimens and great advances in supportive care. The rapid changes in lifestyle, urbanization, and environmental degradation, smoking habit and increasing elderly population are all leading to an increase in patients with airway diseases. Pulmonary diseases are treated by retaining high and prolonged drug concentration in the lungs either administered by pulmonary route or systemic route. Conventional drug delivery of anticancer drugs has a narrow safety range spectrum since a limited amount of drug reaches to the target tumor site. Targeted drug delivery of anticancer drug on tumor site in the lungs can improve the therapeutic effect and it decreases the systemic exposure of the drug.

Fig.1 Ferroptosis in lung adenocarcinoma (LUAD) tumorigenesis and progression.¹

Delivery System Targeting Lung Adenocarcinoma

Recently, a variety of pulmonary drug delivery system suitable for the treatment of lung cancer has been developed. These nanometer and micrometer-sized drug carrier system primarily include nanoparticles, polymer conjugates, polymeric micelles, inhalation nanoparticle, solid lipid nanoparticles, lipid nanocapsules, polymeric nanoparticles, lipid-coated nanoparticles, nanostructured lipid carriers, nanocomposite particles, liposomal drug delivery system, microparticles, and inhalation gene therapy.

Fig.2 The reversion of DNA methylation-induced miRNA silence via biomimetic nanoparticles-mediated gene delivery for efficient lung adenocarcinoma therapy.²

For example, SP5-2 is an imitated peptide mainly bond to NSCLC cells, and liposomal conjugation of SP5-2 increased the magnitude of the drug directly added into NSCLC cells via receptor-controlled endocytosis. Lipo-Dox was made better by active SP5-2 that reduced the adverse effects and enhanced the enduring rate of mice with tumor in metastatic, synergistic and orthotopic animal samples. Results demonstrated that cell tumor had SP5-2-conjugated liposomal DOX (SP5-2-LD) that was 11.2 times increased than free DOX and the environs of the concentration-time curve were amplified 159.2-fold. The bioavailability testing was performed to confirm the efficacy of SP5-2 for in vivo liposomal drug uptake in tumor tissues. The pharmacokinetic properties are elevated by SP5-2-conjugated liposomes that also presented the effectiveness and safety profiles allowing the well-managed drug discharge and biodistribution.

Features of Our Services

• First-class development platform
• Minimal adverse effects
• Enhanced biodistribution profile
• Timely and cost-effective

Creative Biolabs has focused on delivery system technology for years. We have experts who can offer high-quality targeted delivery services for various diseases including lung adenocarcinoma. If you are interested in our targeted delivery discovery services, please contact us for more details.

References

1. Wei, Xiangyun, et al. "Regulation of Ferroptosis in Lung Adenocarcinoma." International Journal of Molecular Sciences 24.19 (2023): 14614.
2. Liang, Lu, et al. "The reversion of DNA methylation-induced miRNA silence via biomimetic nanoparticles-mediated gene delivery for efficient lung adenocarcinoma therapy." Molecular cancer 21.1 (2022): 186.

Our services are For Research Use Only. We do not provide services to individuals.